Australian Clinical Labs Ltd (ASX: ACL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Australian Clinical Labs Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $488.44 million
P/E Ratio 30.81
Dividend Yield 4.24%
Shares Outstanding 201.83 million
Earnings per share 0.077
Dividend per share 0.10
Year To Date Return -17.30%
Earnings Yield 3.25%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Australian Clinical Labs Ltd (ASX: ACL)
    Latest News

    A woman in an office is being pressured, she rubs her temples from the stress.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see which shares short sellers are targeting this week.

    Read more »

    A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
    Cheap Shares

    'Undervalued': 3 ASX 300 shares to buy following significant share price falls

    Experts have named these ASX shares as buys.

    Read more »

    most shorted ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see which shares short sellers are targeting this week.

    Read more »

    A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see which shares short sellers are targeting this week.

    Read more »

    A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
    52-Week Lows

    3 ASX 300 shares hitting new 52-week lows: Are they cheap buys?

    What's sending these shares down to new lows today?

    Read more »

    A bored man sits at his desk, flat after seeing the latest news on the share market.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see why short sellers are betting on these ASX shares sinking.

    Read more »

    a woman with her hands over her face splits her fingers over one eye so she can peep through them.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see why short sellers are betting on these ASX shares sinking.

    Read more »

    A bored woman looking at her computer, it's bad news.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see why short sellers are betting on these ASX shares dropping deep into the red.

    Read more »

    Man holding out $50 and $100 notes in his hands, symbolising ex dividend.
    Dividend Investing

    Popular ASX All Ords shares with ex-dividend dates next week

    Want the next dividend payment on these ASX All Ords shares? Better hurry.

    Read more »

    Kid on a skateboard with cardboard wings soars along the road.
    How to invest

    Shares vs. property: Why cheaper homes and ASX small-cap shares are rising fastest in 2024

    We look into the changing trends in shares vs. property.

    Read more »

    A bored man sits at his desk, flat after seeing the latest news on the share market.
    Earnings Results

    2 ASX 300 shares crashing up to 12% on earnings updates

    These shares are under pressure on Wednesday. Here's why.

    Read more »

    Shot of two young scientists using a laptop in a laboratory.
    Healthcare Shares

    2 ASX healthcare shares with 'compelling' valuations to buy

    The QVE team reckons this pair of small caps can be bought for cheap right now, but could rocket very…

    Read more »

    Frequently Asked Questions

    Yes, Australian Clinical Labs has historically paid two fully franked shareholder dividends a year.

    Australian Clinical Labs generally pays its shareholder dividends in April and September.

    Australian Clinical Labs Ltd listed on the ASX on 14 May 2021.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    28 Mar 2024 $0.0300 100.00% Interim 26 Apr 2024
    27 Mar 2023 $0.0700 100.00% Interim 26 Apr 2023
    23 Aug 2022 $0.4100 100.00% Final 15 Sep 2022
    25 Mar 2022 $0.1200 100.00% Interim 21 Apr 2022

    ACL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Australian Clinical Labs Ltd

    Australian Clinical Labs Ltd (ASX: ACL) is a leading provider of pathology services in Australia. The company's 75 laboratories perform more than 12 million episodes annually with a network of more than 1,300 collection centres in every Australian state and territory except Tasmania. The company is also among the largest private hospital pathology businesses in the country, providing services to more than 90 private and public hospitals.

    Its services include all routine pathology tests, advanced pathology, pregnancy screening, non-invasive prenatal testing, chemical pathology, haematology, histopathology, immunology, serology and microbiology, and commercial drug and alcohol testing. 

    In ACL's established regions of Western Australia, Victoria, New South Wales, Queensland, South Australia, and the Northern Territory, the company has an equivalent market position in community pathology to its rivals Sonic Healthcare Ltd (ASX: SHL) and Healius Ltd (ASX: HLS). The company says it also has a growing presence in the Australian Capital Territory.

    ACL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jun 2024 $2.42 $0.06 2.54% 348,196 $2.39 $2.44 $2.37
    12 Jun 2024 $2.36 $0.05 2.16% 778,782 $2.30 $2.38 $2.30
    11 Jun 2024 $2.31 $0.00 0.00% 347,743 $2.30 $2.32 $2.27
    07 Jun 2024 $2.31 $0.02 0.87% 231,535 $2.29 $2.31 $2.27
    06 Jun 2024 $2.29 $0.04 1.78% 246,928 $2.27 $2.31 $2.27
    05 Jun 2024 $2.25 $-0.03 -1.32% 853,134 $2.28 $2.28 $2.19
    04 Jun 2024 $2.28 $0.00 0.00% 304,350 $2.28 $2.30 $2.25
    03 Jun 2024 $2.28 $-0.01 -0.44% 253,413 $2.27 $2.30 $2.26
    31 May 2024 $2.29 $0.05 2.23% 4,982,463 $2.22 $2.29 $2.20
    30 May 2024 $2.24 $0.04 1.82% 578,595 $2.20 $2.24 $2.14
    29 May 2024 $2.20 $0.04 1.85% 703,706 $2.16 $2.24 $2.15
    28 May 2024 $2.16 $-0.05 -2.26% 802,648 $2.21 $2.21 $2.16
    27 May 2024 $2.21 $0.00 0.00% 772,902 $2.21 $2.21 $2.15
    24 May 2024 $2.21 $0.00 0.00% 277,743 $2.19 $2.21 $2.19
    23 May 2024 $2.21 $0.00 0.00% 594,631 $2.21 $2.24 $2.20
    22 May 2024 $2.21 $-0.12 -5.15% 1,004,124 $2.35 $2.36 $2.21
    21 May 2024 $2.33 $0.01 0.43% 790,065 $2.32 $2.36 $2.24
    20 May 2024 $2.32 $0.02 0.87% 1,232,781 $2.31 $2.33 $2.29
    17 May 2024 $2.30 $-0.14 -5.74% 2,594,970 $2.46 $2.46 $2.30
    16 May 2024 $2.44 $-0.01 -0.41% 886,395 $2.45 $2.49 $2.43
    15 May 2024 $2.45 $-0.10 -3.92% 788,887 $2.55 $2.55 $2.43

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    28 Feb 2024 Christine Bartlett Buy 20,000 $47,154
    On-market trade. As per announcement on 05-03-2024
    20 Dec 2023 Melinda McGrath Issued 395,490 $901,717
    Issue of securities. vwap, 880,836 Rights, As per announcement on 04-01-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Thomas Alscher Non-Executive DirectorNon-Executive Chairman Dec 2020
    Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, specialising in growth companies and certain industry sectors such as healthcare. He is Chair of Risk Committee. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles. He is also member of the Risk Committee.
    Dr Leanne Rowe Non-Executive Director Apr 2021
    Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health, and community health. Leanne is currently a Non-Executive Director of Bupa ANZ Group and a Presiding Member for Medical Panels Victoria.
    Mr Andrew Mark Rendle Dutton Non-Executive Director Apr 2021
    Mr Dutton has over 30 years of management, business development and technology experience across Australia, Asia and Europe. Andrew is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. He is also member of the Risk Committee.
    Mr Nathanial Jonothan Thomson Non-Executive Director Dec 2020
    Mr Thomson is a Partner at Crescent, an Australian private equity investment firm. Nathanial has over 20 years of experience in strategy consulting, private equity, and investment banking. He has consulting experience from his prior role at McKinsey & Co.
    Ms Christine Nildra Bartlett Non-Executive Director Aug 2023
    Ms Bartlett has executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a strong commercial perspective, particularly in fostering innovation and leveraging new emerging technologies.
    Mr Mark Haberlin Non-Executive Director Apr 2021
    Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate, and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is also member of the Risk Committee.
    Ms Melinda Leigh McGrath Chief Executive OfficerExecutive Director Dec 2020
    Ms McGrath has been the Chief Executive Officer and Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Melinda has led the organization's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance-oriented culture across the organization, via one unified integrated pathology system.
    Ms Eleanor Padman Company Secretary
    -
    James Davison Chief Financial Officer
    -
    Eleanor Padman Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Crescent Capital Partners V Lp. 34,579,411 17.13%
    Hsbc Custody Nominees (Australia) Limited 33,314,369 16.51%
    J P Morgan Nominees Australia Pty Limited 25,262,126 12.52%
    Citicorp Nominees Pty Limited 20,122,838 9.97%
    National Nominees Limited 13,940,616 6.91%
    Instanz Nominees Pty Ltd 9,514,668 4.71%
    Ccp Trusco 1 Pty Ltd 8,919,642 4.42%
    BNP Paribas Noms Pty Ltd 5,961,920 2.95%
    Ccp Trusco 2 Pty Ltd 3,908,488 1.93%
    Melinda Mcgrath 2,173,867 1.08%
    Hsbc Custody Nominees (Australia) Limited i 2,131,656 1.06%
    Perpetual Corporate Trust Ltd 2,084,287 1.02%
    Perpetual Corporate Trust Ltd i 1,786,533 0.89%
    ACL Employee Share Trusco Pty Ltd 1,330,743 0.66%
    Mr Nicholas Barry Debenham & Mrs Annette Cecilia Debenham 1,080,800 0.54%
    Dr Anthony James Landgren 838,211 0.42%
    Anthony Friedli 754,390 0.37%
    A.C.N. 633 176 100 Pty Ltd 749,464 0.37%
    Akat Investments Pty Limited 600,000 0.30%
    Paul Gerard Richard 574,649 0.28%

    Profile

    since

    Note